Trial Profile
A phase I study to evaluate the safety and efficacy of first-line nivolumab and ipilimumab in patients with non-small cell lung cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Oct 2015
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Ipilimumab
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 16 Oct 2015 New trial record
- 06 Sep 2015 Results published at 16th World Conference on lung cancer.